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Summary
BACKGROUND AND OBJECTIVE: Clinical decision sup-
port (CDS) might improve management of potassium-in-
creasing drug-drug interactions (DDI). We studied CDS
with five features intended to increase effectiveness: (i) fo-
cus on serious DDIs, (ii) fewer notifications, (iii) presenta-
tion of current laboratory results, (iv) timing (when adverse
event becomes likelier), (v) removal of notification when
appropriate.
METHODS: We conducted a 1-year, hospital-wide, clus-
ter-randomised controlled trial in the inpatient setting at a
large tertiary-care academic medical centre. Three CDS
types were implemented: monitoring reminders (unknown
potassium, no monitoring ordered), elevated potassium
warnings (≥4.9 mEq/l), and hyperkalaemia alerts (≥5.5
mEq/l). The primary endpoint was the frequency of potas-
sium-monitoring intervals >72 h.
RESULTS: We analysed 15,272 and 18,981 stays with
2804 and 2057 potassium-increasing DDIs in the interven-
tion and control groups, respectively. Patient-specific noti-
fications: displayed were 869 reminders (1 per 3.2 potas-
sium-increasing DDIs), 356 warnings (1:7.9), and 62 alerts
(1:45.2). Nevertheless, insufficiently monitored DDIs were
not reduced (intervention 451 of 9686 intervals >72 h
[4.66%]; control 249 of 6140 [4.06%]). The only secondary
outcome improved was the length of potassium monitor-
ing intervals (intervention group mean 22.9 h, control 23.7
h; p <0.001). However, in the intervention group, during
50 of 2804 observed potassium-increasing DDI periods
(1.78%) one or more serum potassium values ≥ 5.5mEq/
l were measured, in the control group, during 27 of 2057
(1.31%; p = 0.20).
CONCLUSIONS: A highly patient-specific CDS feature
combination had a negligible impact on the management
of potentially serious potassium-increasing DDIs and was
unable to improve safety among hospitalised patients.
Trial registration number: The study was registered at
ClinicalTrials.gov (NCT02020317).
Keywords: drug interactions, hyperkalaemia, potassium,
medical order entry systems, electronic health records,
clinical decision support systems, computer-assissted
drug therapy, patient safety, drug monitoring
Background
Drug-drug interactions (DDIs) are an important cause of
adverse drug events and may thereby increase morbidity,
mortality and costs [1–3]. Since recognised DDIs are often
preventable, clinical decision support (CDS) systems have
been developed to automatically detect DDIs and inform
the healthcare providers [4]. However, as a result of in-
sufficient consideration of patient-specific parameters and
variable clinical significance, providers may perceive au-
tomated notifications as annoying and override them [5].
In fact, it has been shown that with a high number of auto-
mated CDS messages the likelihood of overriding increas-
es (‘alert fatigue’), which bears the risk that providers miss
critical notifications [6]. To improve the acceptance and ef-
fectiveness of CDS notifications, various approaches have
been proposed:
– focusing on high-priority DDIs [7]
– displaying context information in notifications such as
current laboratory values [8]
– patient data-driven filtering/suppressing of improper
notifications [9]
– displaying notifications at the right time, when adverse
event becomes likelier [10]
– removing notifications when the triggering conditions
are no longer met [11]
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Whereas CDS interventions usually feature only a few
of these approaches, we designed a concept hereafter de-
scribed that combined all features (a–e) to reduce the num-
ber of CDS notifications and thereby minimise alert fa-
tigue.
Among frequently observed DDIs are potassium-increas-
ing DDIs [12, 13], which are of high clinical significance
because hyperkalaemia can induce potentially fatal cardiac
arrhythmias [14]. Potassium-increasing DDIs are the most
frequent high-priority DDIs at our institution [15]. In our
previous analyses of inpatients’ electronic health record
(EHR) data, we identified patient- and physician-related
risk factors for hyperkalaemia [16] in order to develop
patient-specific models for calculating the risk for hyper-
kalaemia over time during potassium-increasing DDIs
[10]. Based on the model with the highest specificity, we
designed and implemented CDS notifications to improve
care in potassium-increasing DDIs.
The purpose of this cluster-randomised controlled clinical
trial was to determine the impact of our innovative CDS
feature combination on both, process improvements and
occurrences of hyperkalaemia.
Methods
Setting, design, subjects and study period
The study was conducted at the University Hospital
Zurich, a tertiary care academic medical centre in Switzer-
land, which has approximately 850 beds and manages
nearly 40,000 hospital stays per year.
The study was designed as a hospital-wide cluster-ran-
domised controlled trial. Patients were grouped into 29
clusters, and each cluster was a clinical unit for inpatients.
Allocation of the clinical units to either the intervention or
the control group was based on restricted replacement ran-
domisation [17].
All inpatients receiving potassium-increasing DDIs were
included in the study if they were treated in units where
medications were ordered via computerised provider order
entry (CPOE). Intensive care units did not use CPOE dur-
ing the study period, and patient stays on these units were
therefore not considered. Outpatient visits were excluded.
The present CDS intervention was first activated on 7 Jan-
uary 2014, and the study period lasted 1 year. No other au-
tomated CDS was addressing DDIs before or during the
study.
The Cantonal Ethics Committee Zurich (KEK-ZH-Nr.
2013-0507), which is the Institutional Review Board (IRB)
of the University Hospital Zurich, approved the study and
patient consent was waived.
Randomisation procedure
Before the study started, we used the following procedure
to balance the random allocation of the clinical units to the
two study groups.
We retrospectively computed for each study group (i) the
total number of potassium-increasing DDIs and (ii) the
proportion of prolonged potassium monitoring intervals,
defined as the number of intervals >72 hours divided by
the total number of potassium measurement intervals. Im-
portantly, the latter calculation was based on patients with
potassium-increasing DDIs and only considered the mon-
itoring intervals as long as the respective combination of
drugs was active, i.e., as long as the DDI lasted. The
matching was then performed as follows: We accepted the
random allocation of the clinical units if the intervention-
to-control group ratios based on (i) and (ii) were each with-
in the range 2/3 to 3/2 (i.e. maximum difference of 50% for
the number of DDIs and delayed monitoring, respective-
ly). This constraint was applied to control for the frequen-
cy of potassium-increasing DDIs and insufficient potassi-
um monitoring, thereby establishing a balanced allocation
of the clinical units to the
– intervention group: (14 units: abdominal surgerya, car-
diovascular surgerya, emergency department, hematol-
ogyb, infectious diseasesb, internal medicineb, oral and
maxillofacial surgerya, neurologyb, neuroradiology,
pulmonologyb, reconstructive surgerya, rheumatologyb,
traumatologya, urologya) and the
– control group (15 units: angiologyb, cardiologyb, der-
matology, gynecology, endocrinology and diabetologyb,
gastroenterologyb, immunology, nephrologyb, neuro-
surgerya, obstetrics, oncologyb, ophthalmology, otorhi-
nolaryngologya, radiation oncology, thoracic surgerya).
a Surgical units, b internal medicine and related units.
The study team used the software R, version 3.4.0 (R
Foundation for Statistical Computing, Vienna, Austria) for
the randomisation, and enrolled/assigned the clusters to the
intervention and control groups by parameterising the al-
gorithm displaying notifications. Eventually, all included
patients were automatically enrolled and allocated to the
intervention and control groups depending on the unit
where they stayed.
The electronic health record system on site
Since the stepwise introduction of CPOE at the University
Hospital Zurich from 2009 to 2010, inpatient care is com-
prehensively documented and managed by a vendor EHR
system (Kisim, Cistec AG, Zurich, Switzerland). All phar-
macological therapies, other treatments and diagnostic pro-
cedures are ordered via CPOE on all wards except for in-
tensive care units (ICUs). The system offers expandable
CDS functionality with optional consideration of medica-
tion and laboratory data.
DDI knowledge base and potassium-increasing drugs
The regularly updated medication knowledge base galdat/
hospINDEX (distributed to customers within the Swiss
market by HCI Solutions AG, Bern, Switzerland), derived
from ABDATA Pharma-Daten Service (Werbe- und Ver-
triebsgesellschaft Deutscher Apotheker, Eschborn, Ger-
many), is automatically loaded as part of the EHR backend
and integrated into the frontends of the EHR system at our
institution. This knowledge base is available to clinicians
and pharmacologists for reference [15] and was used in
this study to identify potassium-increasing DDIs. Of note,
all DDIs mentioned in this study should be considered
as potential DDIs that did not necessarily induce adverse
events.
The knowledge base tiers DDIs into six levels [18]. The
tiers 1 to 3 indicate serious [19] DDIs: (i) contraindicated,
(ii) contraindicated as precaution, (iii) monitoring or adap-
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tation required. Only these serious potassium-increasing
DDIs were considered by the investigated CDS interven-
tion and in the analyses of this study, whereas the remain-
ing tiers were excluded: (iv) monitoring or adaption in the
case of risk factors, (v) monitoring as a precaution, (vi)
no action required. In the context of this DDI study, drugs
that can induce hyperkalaemia on their own, such as potas-
sium supplements, were only considered in combination
with another drug, according to the DDI definitions of tiers
1 to 3.
Potassium-increasing drugs were defined as drugs in-
volved in serious potassium-increasing DDIs according to
the knowledge base. Among those drugs were angiotensin
converting-enzyme inhibitors (ACE inhibitors), an-
giotensin antagonists (angiotensin-receptor blockers), di-
rect renin inhibitors, immunosuppressive agents (cal-
cineurin inhibitors), potassium-sparing diuretics
(aldosterone receptor antagonists and epithelial sodium
channel blockers), potassium supplements and trimetho-
prim.
The algorithm displaying electronic notifications
Electronic notifications were displayed only in the EHRs
of patients hospitalised in the units of the intervention
group, identically visible to physicians and nurses, and
they were displayed only as long as the triggering con-
ditions were met. The display of the notifications was
suppressed in the control group. Nevertheless, data from
both study groups were consistently collected in the back-
ground.
At onset of and during potassium-increasing DDIs the al-
gorithm checked whether a current serum potassium value
was available, and if so, whether the potassium level was
elevated. Otherwise, the algorithm checked if a potassium
level measurement had been ordered. Three types of elec-
tronic notifications could be displayed as a result of these
checks:
– Reminders:
– If the most recent potassium measurement was more
than 48 hours previously and no monitoring had been
planned, the algorithm displayed a reminder that sug-
gested ordering a serum potassium measurement.
– Warnings:
– If the current serum potassium value was ≥4.9 mEq/l,
the CDS warned against the increasing risk of hyper-
kalemia.
– Alerts:
– If the current serum potassium value was ≥ 5.5 mEq/l, a
notification was displayed alerting the provider about a
hyperkalemic state of the patient [20].
Reminders, warnings and alerts each appeared as a non-in-
terruptive red bar in the top section of the EHR (a screen-
shot of a similar CDS notification bar has been published
elsewhere [21]). By clicking on this bar, a pop-up window
was displayed that notified the provider of the reason for
the intervention, the prescribed potassium-increasing DDI,
the most recent serum potassium value, the creatinine and
the glomerular filtration rate, and it also included sugges-
tions how to proceed. The preferred action could direct-
ly be initiated by a single click on one of these suggest-
ed options. Two additional buttons referred to all identified
DDIs, and to further general information. Although all no-
tifications were visible to both physicians and nurses, only
physicians had the ability to choose options in the pop-up
windows.
Primary and secondary endpoints
The primary endpoint for assessing the impact of the inter-
vention was the frequency of prolonged potassium-moni-
toring intervals during potassium-increasing DDIs, defined
as periods without any potassium level measurement last-
ing longer than 72 hours. When a potassium measurement
was ordered, the monitoring interval was immediately re-
duced to this point in time (shortening the monitoring pe-
riod). Also, when a DDI was discontinued, the monitoring
interval was immediately reduced to the timepoint of DDI
discontinuation.
The secondary endpoints of the study included the mean
length in hours of potassium monitoring intervals during
DDIs, the frequency of hyperkalaemic patient states during
DDIs, the frequency of potassium-increasing DDIs ordered
for patients with hyperkalaemia, the mortality related to
hyperkalaemia (within 48 hours after occurrence of hyper-
kalaemia), and finally provider responses to the CDS noti-
fications in the intervention group (which were automati-
cally assigned in the control group merely for comparison
purposes).
Sample size calculation, data processing and statistics
Based on a retrospective analysis of EHR data, we estimat-
ed that the proportion of prolonged monitoring intervals
could be reduced in the intervention group from 6% to 5%.
With a type I error rate of 0.05 and a power of 80%, we
calculated a sample size of 6426 monitoring intervals for
each study group. The study period of one year additional-
ly addressed potential concerns about seasonal influences
[22].
Routinely collected EHR data were extracted from the
clinical data warehouse, exported to raw data files, which
in turn were imported into a separate database management
system and processed using structured query language
(SQL) statements.
Statistics were computed using the software R, version
3.4.0 (R Foundation for Statistical Computing, Vienna,
Austria). Group comparisons of continuous variables were
performed using the Wilcoxon rank-sum test. Group com-
parisons of proportions were performed using the Fisher’s
exact test. Hereafter, p-values of ≤0.05 are considered to be
statistically significant.
Results
We analysed data of 34,253 inpatient stays, as shown in
table 1. These patients received 922,121 medications dur-
ing the study period, resulting in a total of 4861 potassium
increasing DDIs.
Clinical endpoints
The analysis of the primary endpoint showed that the fre-
quency of insufficiently monitored DDI periods was not
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reduced by the monitoring reminders. In the intervention
group, 4.66% (451 of 9686) potassium-monitoring periods
lasted >72 h, compared with the control group, where
4.06% (249 of 6140) prolonged monitoring periods were
found. Independent of the study groups, we found that pa-
tients treated in internal medicine and related units had
prolonged monitoring intervals in 4.32% of cases and
those in surgical units in 3.50%.
However, a statistically significant difference was ob-
served for one secondary endpoint. The mean length of the
potassium monitoring intervals during DDIs was slightly
shorter in the intervention group (22.9 h) compared with
the control group (23.7 h; p <0.001).
No benefit was found with respect to other secondary end-
points. In the intervention group, during 50 of 2804 ob-
served potassium-increasing DDI periods (1.78%) a serum
potassium value ≥5.5 mEq/l was measured at least once.
In the control group, during 27 of 2057 potassium-increas-
ing DDI periods (1.31%) one or more serum potassium
values ≥5.5mEq/l were detected (p = 0.20). In the inter-
vention group, seven potassium-increasing DDIs (0.25%)
were ordered in the presence of hyperkalaemia, in the con-
trol group ten (0.49%; p = 0.22).
In the intervention group 22 patients died during the study,
in the control group 14; however, none of these fatalities
were related to hyperkalaemia.
CDS notifications, provider responses and events
The providers in the intervention group could acknowledge
the notification or enter override reasons, whereas all re-
sults of the control group had to be evaluated automatical-
ly, based on electronically available data recorded after a
notification had been suppressed. For comparison purpos-
es, the respective data from the intervention group were
analogously evaluated.
Table 2 reports the number of CDS notifications by type
and categorised provider responses. In a relatively small
proportion of cases the notifications were triggered again
after the providers announced plans to monitor potassium
or to discontinue the DDI but did not implement their in-
tentions. For instance, providers ordered 412 potassium
levels and announced further measurements; however, the
lack of implementation caused the display of 38 additional
reminders summing up to 450.
In the evaluation of events recorded, the most notable dif-
ference between the two study groups were the higher
Table 1: Characteristics of hospitalised patients, important comorbidities [23], and factors related to serious potassium-increasing DDIs by study group.
. Intervention group Control group
Number of hospitalisations 15,272 18,981
Hospitalisations of females 6225 11,360
Hospitalisations of males 9047 7621
Mean age of patients (years) 55.7 53.1
Hospitalisations of patients with renal impairment 1618 1863
Hospitalisations of patients with diabetes mellitus 1636 1813
Mean number of medications ordered 32.3 22.6
Mean baseline potassium level (mmol/l) 3.97 4.23
Number of potassium-increasing DDIs 2804 2057
Table 2: Events and providers’ actions during the period of displaying and suppressing the notifications in the intervention and control group, respectively.
Intervention Control
Intervention group: Displayed notifica-
tions with providers' responses and ac-
tions
Count % Evaluation based on events
recorded
Count % Count %
Monitoring reminder New potassium level available or mea-
surement planned
24 2.8 New potassium level available 24 3.0 14 3.1
Potassium measurement ordered or
planned
450 51.8 Potassium measurement ordered 412 52.0 224 49.3
Potassium-increasing DDI discontinued
or discontinuation planned
361 41.5 Potassium-increasing DDI discon-
tinued
357 45.0 216 47.6
CDS notification acknowledged 31 3.6
No reaction for 10 days (until expiration
of CDS notification)
3 0.3
Subtotal, monitoring reminder 869 100.0 Subtotal, monitoring reminder 793 100.0 454 100.0
Warning against increased
risk of hyperkalaemia
New potassium level available or mea-
surement planned
216 60.7 New potassium level available 214 66.3 155 73.5
Potassium-increasing DDI discontinued
or discontinuation planned
129 36.2 Potassium-increasing DDI discon-
tinued
109 33.7 56 26.5
CDS notification acknowledged 11 3.1
Subtotal warning against increased
risk of hyperkalaemia
356 100.0 Subtotal, warning against in-
creased risk of hyperkalaemia
323 100.0 211 100.0
Hyperkalaemia alert New potassium level available or mea-
surement planned
46 74.2 New potassium level available 46 78.0 46 73.0
Potassium-increasing DDI discontinued
or discontinuation planned
16 25.8 Potassium-increasing DDI discon-
tinued
13 22.0 17 27.0
Subtotal,
hyperkalaemia alert
62 100.0 Subtotal, hyperkalemia alert 59 100.0 63 100.0
Total intervention group 1287 Total 1175 728
DDI: Drug-drug interaction
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numbers of reminders and warnings in the intervention
group, explainable by an increased number of medication
orders inducing more potassium-increasing DDIs in the in-
tervention group (cf. table 1).
Patient-specific notifications
Based on the number of displayed notifications and the
number of potassium-increasing DDIs in the intervention
group (2804) we calculated ratios to illustrate the intended
reduction of the number of notifications.
A total of 869 reminders to monitor potassium were dis-
played, representing a ratio of 1 per 3.2 potassium-increas-
ing DDIs, 356 notifications warned against the risk of a hy-
perkalaemia (1 per 7.9 DDIs), and 62 hyperkalaemia alerts
were triggered (1 per 45.2 DDIs). These ratios compare
favorably to a hypothetical (but common) concept of dis-
playing notifications during order entry for each potassi-
um-increasing DDI. If the 62 episodes of hyperkalaemia
were the direct result of the 2804 potassium-increasing
DDIs in the intervention group, then the concept of dis-
playing notifications during order entry would have had a
positive predictive value of only 2.2%. This is in line with
a retrospective analysis previously performed at our insti-
tution [10].
Discussion
We implemented an innovative, comprehensive and highly
patient-specific alert concept to improve safety during
potassium-increasing DDIs and to minimise the risk of
overriding and alert fatigue. Although the electronic notifi-
cations had no significant impact on clinical endpoints, we
observed a statistically significant reduction of the length
of potassium monitoring intervals. However, this modest
reduction of the time to monitor the potassium serum level
from 23.7 to 22.9 hours may have improved the process
– at best – and is of very limited clinical significance. All
other endpoints were not influenced as intended. Our clus-
ter-randomised controlled trial showed no impact on poor-
ly monitored DDIs with monitoring intervals longer than
72 hours and we were unable to reduce the number of hy-
perkalaemia occurrences. We therefore question the effec-
tiveness of CDS interventions against DDIs, which has al-
so been questioned by others [24].
Duke at al. [8] performed a similar study in the outpatient
setting to investigate “context enhanced” DDI alerts for pa-
tients at risk of hyperkalaemia. To our knowledge, this has
been the only study so far that also targeted a broad range
of DDIs increasing a patient’s serum potassium, based on
the automated detection of “six class interactions (combi-
natorial of ACE inhibitors, angiotensin receptor blockers,
potassium-sparing diuretics, and potassium supplements)”.
This context-enhanced type of DDI alert, if displayed to
a provider of the intervention group, included information
on the triggering DDI, and the current potassium and cre-
atinine levels. Importantly, in their study the control group
was also notified of potassium-increasing DDIs but with-
out additional information on laboratory measurements.
The study by Duke et al. [8] was unable to show any
improvements of the providers’ adherence and concluded
that context-enhanced alerts were not superior to the usual
ones. In our study, however, the notifications were com-
pletely withheld from the control group.
The literature on automated monitoring reminders distin-
guishes between synchronous and asynchronous notifica-
tions [25]. There are published studies showing successful
interventions synchronous to the ordering process [26] –
sometimes considered as “corollary orders” [27] – as well
as of asynchronous monitoring reminders [25]. Some of
these publications do mention a form of monitoring re-
minders targeted at potassium levels; however, one did not
report on related outcomes [27], and the other investigated
alerts of low potassium levels during treatment with digox-
in [25]. Therefore, the comparability with our study is lim-
ited. Our reminders and alerts were non-interruptive and
were asynchronously displayed, but – depending on potas-
sium levels electronically available at the time of ordering
– notifications may have been displayed before or imme-
diately after completing the order. As opposed to non-in-
terruptive designs, interruptive CDS has been linked to
patient safety concerns; for instance, one group reported
that CDS against warfarin trimethoprim-sulfamethoxazole
DDIs caused unacceptable treatment delays [28, 29].
In comparison to published recommendations [30], our
CDS notifications featured various assets, such as
– consideration of current laboratory values in the CDS
logic to reduce the alert burden and minimise the risk
for alert fatigue,
– non-interruptive notification bar linking to information
window that is accessible on demand,
– distinct colours for each notification type within the re-
spective information windows of reminders, warnings,
and alerts, indicating seriousness,
– presentation of interacting drug pair and patient-specif-
ic context including laboratory values,
– concise instructions with minimal text, signal words
and provision of potential clinical consequences,
– suggested options (e.g., order potassium measurement)
directly available from the information window,
– further details available via links,
– possibility to enter override reasons which were rou-
tinely collected,
– and further patient-specific DDI checks – for all poten-
tial DDIs featured in the comprehensive knowledge
base used – could be triggered on demand [15],
while other recommended features were lacking, i.e.,
– there was no explicit provision of specific evidence for
the seriousness of the DDI or the underlying mecha-
nism,
– none of the CDS types was interruptive, even when hy-
perkalemia was detected,
– our asynchronous notifications may have been dis-
played shortly after the time of decision making (but
stayed visible a lengthy period),
– providers were unable to turn notifications permanently
off, and no “snooze” function was available,
– presentation of notifications did not vary by clinician
type,
– notifications could not be forwarded by a single click to
others,
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– and patients could access neither information of their
EHR, nor on CDS notifications via patient portals.
In summary, we used an innovative, highly patient-specific
combination of CDS features intended to improve adher-
ence to electronic notifications and to reduce overriding
and minimise the risk for alert fatigue. Among the features
was a functionality that displayed the triggering potassium-
increasing DDI, the most recent serum potassium value
and the glomerular filtration rate. The intervention targeted
the most frequent high-priority DDI at our institution. The
hospital-wide study was conducted at a large tertiary care
academic medical centre, a leading teaching hospital in
Switzerland that comprehensively manages inpatient care
by a state-of-the-art EHR system.
Randomisation procedures for hospital-wide controlled tri-
als investigating clinical decision support are challenging.
The standard approach of randomising individual patients
carries the risk of contamination due to the fact that the
physician will receive notifications for some patients but
not for all. On the one hand, the effect of notifications re-
ceived for patients in the intervention group might influ-
ence the reasoning and actions of a physician when car-
ing for patients of the control group, potentially having an
impact on the control group as well. On the other hand,
providers might feel unreasonably confident that they
would receive notifications by the system for any patient,
despite a potential allocation of a patient to the control
group, which might introduce patient safety risks. We
therefore randomised the 29 clinical units. Hereby, cont-
amination was limited to situations where a physician in
charge asked for advice from a consultant of a unit allocat-
ed to the other study arm. In order to ensure the best pos-
sible comparability of the two study groups in regard of
our endpoints, a balanced cluster randomisation was used.
However, this balancing method does not necessarily pre-
vent uneven distributions of all patient and study parame-
ters between the two groups.
Our study has additional limitations that need to be taken
into account in interpreting the results. It was a single cen-
tre trial and only inpatient data were available, whereas
approaches for outpatient follow-up were not considered
and therefore patient outcomes after discharge remain un-
known. Some work related to that specific area has re-
cently been done by Saito et al. [31]. Furthermore, we
processed large amounts of routinely collected EHR data
but we did not additionally perform chart reviews to iden-
tify potential adverse drug events (ADEs) induced by hy-
perkalaemic states that might have been insufficiently ad-
dressed by our approaches. However, the only endpoint
that differed between the study groups as intended showed
a negligible impact of our intervention, and no meaningful
difference in the ADE incidences would be expected as
a consequence of a 0.8 hours (3.4%) shorter monitoring
interval. Finally, comparing the in-hospital mortality be-
tween the study groups lacked any consideration of con-
founders; however, none of the patients died because of
hyperkalaemia during the study.
It should be noted that we measured mean monitoring peri-
ods of <24 hours, indicating an already high quality of care
in the context of the considered DDIs. This contributes to
the inherent methodological challenge arising from a rela-
tively low incidence of serious potassium homeostasis dis-
orders and resulting ADEs induced by potassium-increas-
ing DDIs. It appears that the potential to improve patient
safety was limited despite a high DDI frequency.
Although there is a broad range of evidence on the ability
of CDS to improve processes, only a few results are avail-
able that support the viewpoint that CDS also improves pa-
tient outcomes [32, 33]. Our study particularly challenges
the usefulness of automated notifications about potassium-
increasing DDIs despite a low alert burden. In this context,
we increasingly question the justification for both (i) di-
rect costs due to research, development and maintenance
of the information technology and (ii) indirect expenses
due to the burden providers experience in handling clin-
ically insignificant notifications that are to be appropri-
ately overridden [5, 34]. Ultimately, even if potassium-in-
creasing DDIs were to clearly increase mortality due to
serious hyperkalaemic states with fatal cardiac arrhyth-
mias, CDS could still not guarantee clinical effectiveness,
which is hampered by high override rates [5]. The need
for outcome studies investigating the true clinical impact
of DDIs has recently been advocated [35], and therefore,
future research should focus on CDS targeting evidence-
based clinical consequences that are frequent and serious,
as opposed to frequent and perhaps serious DDIs. Addi-
tional considerations for future studies include qualitative
research and focus group discussions on human factors and
usability, testing populations with important comorbidi-
ties such as diabetes and renal failure, combination out-
comes that take into account all of the providers’ options
to handle clinical issues and different CDS types, and ran-
domised controlled trials with the patients or the providers
as units of randomisation.
In conclusion, our asynchronous, highly patient-specific,
innovative CDS feature combination was unsuccessful in
improving patient safety in terms of the most frequent
high-priority DDI at our institution.
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